Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 10 clinical trials
Prospective Evaluation of Hypofractionated Stereotactic RT Using CyberKnife for Patients With Prostate Cancer

The main purpose of study is to evaluate hypofractionated stereotactic radiotherapy (SBRT) using CyberKnife for Patients with low and intermediate risk of progression prostate cancer.

adenocarcinoma
adenocarcinoma of prostate
metastasis
  • 4 views
  • 23 Jan, 2021
  • 1 location
Cyclin D1 Based TPF(Docetaxel, Cisplatin and 5-fluorouracil) Induction Chemotherapy for OSCC(Oral Squamous Cell Carcinoma) Patients at cN2(Clinical Node 2) Stage: a Phase II Randomized Controlled Trial

The purpose of this study is to To confirm the predictive value of CCND1 for TPF induction in cN2 patients with OSCC

cancer
carcinoma
chemotherapy regimen
caries
squamous cell carcinoma
  • 19 views
  • 20 Oct, 2022
  • 1 location
A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer

biomarkers than those who receive placebo. Cyclin D1 will serve as the primary biomarker. This investigation will determine whether subjects randomized to UAB30 have an increase in all trans-retinoic

cancer
skin cancer
basal cell carcinomas
hysterectomy
squamous cell carcinoma
  • 0 views
  • 02 Sep, 2023
  • 1 location
Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration

This is a single-arm, phase II study that will enroll a total of 45 subjects. All subjects will have a confirmed diagnosis of metastatic or unresectable soft tissue sarcoma or bone sarcoma. All subjects must have intact Rb, identified at the time of screening, by immunohistochemistry testing of submitted tumor …

renal function
glomerular filtration rate
immunomodulators
neutrophil count
kidney function tests
  • 11 views
  • 08 Apr, 2023
  • 5 locations
9-ING-41 in Patients With Advanced Cancers

GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.

HER2
cancer
serum amylase
absolute neutrophil count
epidermal growth factor
  • 795 views
  • 24 Aug, 2023
  • 27 locations
Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)

Based on different HR status, we explored the efficacy and safety of Pyrotinib and Dalpiciclib Isethionate Tablets based combination regimen in the first-line treatment of HER2 + MBC.

HER2
estrogen receptor
epidermal growth factor
measurable disease
endocrine therapy
  • 0 views
  • 15 Jun, 2022
  • 1 location
Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced Prostate Cancer (RAD 1805)

This Phase II study is designed to study the clinical and radiologic response, as well as, safety and tolerability of abemaciclib in combination with androgen deprivation therapy (ADT) in patients with localized high-risk or locally advanced prostate cancer who are eligible for definitive radiation therapy (RT) and androgen deprivation therapy …

  • 0 views
  • 04 Apr, 2023
  • 1 location
A Phase I/II Study of Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma

Background Kaposi Sarcoma (KS) is common in people with human immunodeficiency virus (HIV) but can also occur in people who do not have HIV. KS tumors usually involve the skin, but may also involve lymph nodes, lungs, bone, and gastrointestinal tract. Researchers want to see if a drug that is …

cancer
cytotoxic chemotherapy
protease
progressive disease
atazanavir
  • 0 views
  • 25 Oct, 2022
  • 1 location
Ibrutinib Combined With Bendamustine and Rituximab in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged > 65 Years

This study is a prospective observational clinical trial. A total of 19 research centers were involved in this study. Each site plans to enroll 2-3 patients, and a total of 60 patients will be enrolled. Patients who met the diagnosis of mantle cell lymphoma by histological examination, ECOG (Eastern Oncology …

ibrutinib
bendamustine
mantle cell lymphoma
rituximab
r-chop
  • 0 views
  • 13 Jun, 2022
  • 1 location
Ibrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged ≤65 Years

The purpose of the study is to better and systematically collect clinical data on the treatment of ibrutinib combined with R-CHOP/DHAP regimen for more scientific and accurate evaluation, our center has carried out the R-CHOP/R-DHAP alternative regimen combined with ibrutinib at age ≤ An observational clinical study on the safety …

ibrutinib
mantle cell lymphoma
r-chop
chop regimen
measurable disease
  • 0 views
  • 11 Jul, 2022
  • 1 location